Reducing Uncertainty in the Care and Treatment of Blood Cancer ST. LOUIS, MO, UNITED STATES, February 23, 2026 ...

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...

These abstracts and posters will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, which will be held Feb. 26-28 at the Moscone West Conference Center, ...

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...

Chief Medical Officer Zach Roberts said the company expects to report initial data in April from its ALPHA3 study, a frontline consolidation trial evaluating its off-the-shelf allogeneic CD19 CAR ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...

A looming revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster biotech stocks like Guardant Health, Natera and Exact Sciences. And all it takes is a little blood.

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies. Quest Diagnostics has announced the launch of a novel ...

Minimal residual disease, or MRD, testing may have the potential to offer peace of mind to survivors of breast cancer, as a ...